Suppr超能文献

强化化疗联合受累野剂量降低放疗治疗早期不良预后霍奇金淋巴瘤患者:德国霍奇金研究组 HD11 试验的最终分析。

Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.

机构信息

University of Cologne, German Hodgkin Study Group, Köln, Germany.

出版信息

J Clin Oncol. 2010 Sep 20;28(27):4199-206. doi: 10.1200/JCO.2010.29.8018. Epub 2010 Aug 16.

Abstract

PURPOSE

Combined-modality treatment consisting of four to six cycles of chemotherapy followed by involved-field radiotherapy (IFRT) is the standard of care for patients with early unfavorable Hodgkin's lymphoma (HL). It is unclear whether treatment results can be improved with more intensive chemotherapy and which radiation dose needs to be applied.

PATIENTS AND METHODS

Patients age 16 to 75 years with newly diagnosed early unfavorable HL were randomly assigned in a 2 × 2 factorial design to one of the following treatment arms: four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy of IFRT; four cycles of ABVD + 20 Gy of IFRT; four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP(baseline)) + 30 Gy of IFRT; or four cycles of BEACOPP(baseline) + 20 Gy of IFRT.

RESULTS

With a total of 1,395 patients included, the freedom from treatment failure (FFTF) at 5 years was 85.0%, overall survival was 94.5%, and progression-free survival was 86.0%. BEACOPP(baseline) was more effective than ABVD when followed by 20 Gy of IFRT (5-year FFTF difference, 5.7%; 95% CI, 0.1% to 11.3%). However, there was no difference between BEACOPP(baseline) and ABVD when followed by 30 Gy of IFRT (5-year FFTF difference, 1.6%; 95% CI, -3.6% to 6.9%). Similar results were observed for the radiotherapy question; after four cycles of BEACOPP(baseline), 20 Gy was not inferior to 30 Gy (5-year FFTF difference, -0.8%; 95% CI, -5.8% to 4.2%), whereas inferiority of 20 Gy cannot be excluded after four cycles of ABVD (5-year FFTF difference, -4.7%; 95% CI, -10.3% to 0.8%). Treatment-related toxicity occurred more often in the arms with more intensive therapy.

CONCLUSION

Moderate dose escalation using BEACOPP(baseline) did not significantly improve outcome in early unfavorable HL. Four cycles of ABVD should be followed by 30 Gy of IFRT.

摘要

目的

对于早期不良霍奇金淋巴瘤(HL)患者,包含四至六个周期化疗和累及野放疗(IFRT)的联合治疗是标准的治疗方法。目前尚不清楚是否可以通过更强化的化疗来提高治疗效果,以及需要应用何种剂量的放疗。

患者和方法

年龄在 16 至 75 岁之间的新诊断为早期不良 HL 患者,以 2×2 析因设计随机分配至以下治疗组之一:ABVD(多柔比星、博来霉素、长春碱和达卡巴嗪)加 30Gy IFRT(4 个周期);ABVD 加 20Gy IFRT(4 个周期);BEACOPP(基线)加 30Gy IFRT(4 个周期);BEACOPP(基线)加 20Gy IFRT(4 个周期)。

结果

共纳入 1395 例患者,5 年无治疗失败率(FFTF)为 85.0%,总生存率为 94.5%,无进展生存率为 86.0%。BEACOPP(基线)在接受 20Gy IFRT 治疗时比 ABVD 更有效(5 年 FFTF 差异,5.7%;95%CI,0.1%至 11.3%)。然而,当接受 30Gy IFRT 治疗时,BEACOPP(基线)与 ABVD 之间没有差异(5 年 FFTF 差异,1.6%;95%CI,-3.6%至 6.9%)。对于放疗问题也观察到了类似的结果;在接受四个周期的 BEACOPP(基线)治疗后,20Gy 并不劣于 30Gy(5 年 FFTF 差异,-0.8%;95%CI,-5.8%至 4.2%),而在接受四个周期的 ABVD 治疗后,20Gy 劣于 30Gy(5 年 FFTF 差异,-4.7%;95%CI,-10.3%至 0.8%)。接受强化治疗的患者毒性反应更常见。

结论

使用 BEACOPP(基线)进行适度剂量升级并未显著改善早期不良 HL 的预后。ABVD 应加 30Gy IFRT。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验